CORDIS
EU research results

CORDIS

English EN

SME Led Malaria Vaccine Initiative

Project information

Grant agreement ID: 18918

  • Start date

    1 February 2006

  • End date

    31 January 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 2 828 542

  • EU contribution

    € 1 696 405

Coordinated by:

ETNA BIOTECH S.R.L.

Italy

Objective

This SME coordinated and dominated STREP will investigate new malaria vaccine candidates with the objective of taking at least one through to GLP pilot scale up. The most promising candidates will undergo in vitro and in vivo testing, lead optimisation, safety and toxicology testing according to GLP standards. The combination of efforts presented in this STREP will generate several recombinant measles viruses expressing a variety of malaria antigens based primarily upon MSP-1 and secondarily on AMA-1.

In order to maximise on the capabilities of the SMEs and two of the leading European malaria research institutes, this STREP will concentrate on six workpackages: WP1 Project Management; WP2 Development of transgenic humanised mice, Delivery of malaria antigen coding sequences; WP3 Delivery of block 2 malaria antigens; WP4 Hybrid malaria antigen development, Primate challenge studies; WP5 Development of MeVs expressing multiple blood stage malaria antigens; WP6 Validation and Biosafety evaluation of candidate vaccines.

The timeframe and budget allocated directly reflect the requirements for such a proposal, including contingency plans. In addition, this STREP application, coordinated by EtnaVax, will compliment the detailed work laid out in other larg er European research projects and proposals. As such it forms an essential stepping-stone in the trans-European malaria vaccine initiative.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ETNA BIOTECH S.R.L.

Address

Piazza Stesicoro 59
Catania

Italy

Participants (3)

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE

Netherlands

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

UNIVERSITY OF EDINBURGH

United Kingdom

Project information

Grant agreement ID: 18918

  • Start date

    1 February 2006

  • End date

    31 January 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 2 828 542

  • EU contribution

    € 1 696 405

Coordinated by:

ETNA BIOTECH S.R.L.

Italy